It is important to consider the total cost of care (TCOC) associated with a therapy and clin. benefit for relapsed or refractory (R/R) large B cell lymphoma (LBCL).We estimated the 1-yr TCOC and cost per clin. outcome for patients with R/R LBCL treated with second-line lisocabtagene maraleucel (liso-cel) vs. autologous stem cell transplantation (ASCT) using data from the TRANSFORM study (ClinicalTrials.gov NCT03575351).A cost per clin. outcome anal. using a Monte Carlo simulation approach was conducted.Cost inputs were generated from a retrospective microcosting anal. of healthcare resource utilization (HCRU).Patient-level data from an interim anal. (March 2021) were used to derive HCRU and clin. inputs.Clin. inputs included median event-free survival (EFS), median progression-free survival (PFS), objective response rate, and complete response (CR) rate.In the intention-to-treat anal., the mean (standard deviation) TCOC per patient was $550,864 ($173,087) for liso-cel and $413,200 ($290,802) for ASCT.The cost per clin. outcome model estimated a mean cost for liso-cel vs. ASCT per EFS month of $57,295 vs. $186,369, per PFS month of $40,949 vs. $78,797, per overall responder of $653,965 vs. $881,804, and per complete responder of $828,045 vs. $1,063,822.This economic model shows reductions in mean estimated TCOC per EFS month, PFS month, overall responder, and complete responder with liso-cel vs. ASCT owing to the superior efficacy of liso-cel.Although liso-cel-treated patients incurred greater upfront costs, fewer required subsequent therapy, and they accumulated less downstream costs.These results underscore the importance of considering the durability of response and clin. benefit when assessing total costs.